open access

Vol 85, No 8 (2014)
ARTICLES
Get Citation

Diagnostic utility of RHD-gene detection in maternal plasma in the prophylaxis of feto-maternal Rh-incompatibility

Agnieszka Sapa, Mieczysław Woźniak, Anna Jonkisz, Mariusz Zimmer, Artur Kłósek
DOI: 10.17772/gp/1772
·
Ginekol Pol 2014;85(8).

open access

Vol 85, No 8 (2014)
ARTICLES

Abstract

Objectives: The aim of the study was analytical validation of prenatal noninvasive fetal RHD detection in maternal plasma and the preliminary assessment of its clinical utility. Introduction of this noninvasive test into routine diagnostic use is important for more rational and safe immunoprophylaxis. Material and methods: RHD gene was detected using real-time PCR. Primers and probes complementary to sequence on exons 7 and 10 were chosen. Samples with RHD-negative results were examined with additional tests to confirm the proper isolation of cell-free fetal DNA (cffDNA). For male fetuses, the presence of fetal DNA was confirmed by detection of the male genetic marker (SRY gene) using Quantifiler DuoR kit. In the case of SRY-negative result we used mini SGM test, which is based on the detection of short-tandem repeat polymorphism differences between maternal and fetal DNA. Results: Diagnostic accuracy of RHD test was 96.82%, while diagnostic value of SRY determination was lower (87.50%). Mini SGM test was able to confirm the presence of fetal DNA in 77% of the cases. Conclusions: Effectiveness of the proposed procedure of prenatal noninvasive RHD determination and cffDNA confirmation is high, on condition proper control samples and suitable verifying tests are used.

Abstract

Objectives: The aim of the study was analytical validation of prenatal noninvasive fetal RHD detection in maternal plasma and the preliminary assessment of its clinical utility. Introduction of this noninvasive test into routine diagnostic use is important for more rational and safe immunoprophylaxis. Material and methods: RHD gene was detected using real-time PCR. Primers and probes complementary to sequence on exons 7 and 10 were chosen. Samples with RHD-negative results were examined with additional tests to confirm the proper isolation of cell-free fetal DNA (cffDNA). For male fetuses, the presence of fetal DNA was confirmed by detection of the male genetic marker (SRY gene) using Quantifiler DuoR kit. In the case of SRY-negative result we used mini SGM test, which is based on the detection of short-tandem repeat polymorphism differences between maternal and fetal DNA. Results: Diagnostic accuracy of RHD test was 96.82%, while diagnostic value of SRY determination was lower (87.50%). Mini SGM test was able to confirm the presence of fetal DNA in 77% of the cases. Conclusions: Effectiveness of the proposed procedure of prenatal noninvasive RHD determination and cffDNA confirmation is high, on condition proper control samples and suitable verifying tests are used.
Get Citation

Keywords

cell-free fetal DNA, RhD gene, feto-maternal incompatibility, prenatal noninvasive diagnosis

About this article
Title

Diagnostic utility of RHD-gene detection in maternal plasma in the prophylaxis of feto-maternal Rh-incompatibility

Journal

Ginekologia Polska

Issue

Vol 85, No 8 (2014)

DOI

10.17772/gp/1772

Bibliographic record

Ginekol Pol 2014;85(8).

Keywords

cell-free fetal DNA
RhD gene
feto-maternal incompatibility
prenatal noninvasive diagnosis

Authors

Agnieszka Sapa
Mieczysław Woźniak
Anna Jonkisz
Mariusz Zimmer
Artur Kłósek

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl